Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
07 Octobre 2024 - 2:30PM
Impact BioMedical Inc. (NYSE American: IBO), a pioneering
biotechnology company dedicated to discovering, developing, and
patenting innovative healthcare solutions, is pleased to announce
the successful completion of its Initial Public Offering (IPO).
Notable is that over 30% of the IPO was purchased by existing
investors which further demonstrates strong belief in the company
and its potential.
Frank D. Heuszel, CEO of Impact BioMedical, commented, "The
significant participation of our investors underscores their
confidence in our mission and the innovative healthcare solutions
we are developing. Their support is a testament to the value they
see in our work and our potential to make a meaningful impact on
human health."
About Impact BioMedical, Inc.:
Impact BioMedical Inc. (NYSE American: IBO) discovers, confirms,
and patents unique science and technologies which can be developed
into new offerings in biopharmaceuticals and consumer healthcare
and wellness in collaboration with external partners through
research, licensing, co-development, joint ventures, and other
relationships.
Safe Harbor Disclosure:This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date.
Media Contact:Mark Suseck Email:
mark.suseck@impactbiomedinc.com
Investor Relations:info@impactbiomedinc.com
Impact Biomedical (AMEX:IBO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Impact Biomedical (AMEX:IBO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024